+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 3
Age: 18Years - 75Years
FEMALE
ID06977893

Phase III Study of Neoadjuvant Chemotherapy with Toripalimab Versus Chemotherapy Alone for HRHER2- Breast Cancer

Led by First Affiliated Hospital of Zhejiang University · Updated on 2025-05-18

194

Participants Needed

13

Research Sites

156 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating the effectiveness and safety of neoadjuvant chemotherapy combined with Toripalimab for women with HRHER2- breast cancer in this randomized, open-label, phase III study. The goal is to explore treatment strategies combining chemotherapy with immunotherapy to provide more options and a potential basis for precision treatment of this breast cancer subtype. The main focus is to assess the rate of complete pathological response and RCB0-1 ratio after neoadjuvant treatment. Participants are assigned to one of two groups one receives neoadjuvant chemotherapy combined with Toripalimab, and the other receives neoadjuvant chemotherapy alone. The chemotherapy includes intravenous infusions of Epirubicin or liposomal doxorubicin plus Cyclophosphamide for 12 weeks, followed by Paclitaxel every 3 weeks for 12 weeks. The group receiving Toripalimab will have additional intravenous infusions of 240 mg every 3 weeks during both neoadjuvant chemotherapy and postoperative adjuvant therapy for a total duration of one year. During the study, participants will undergo various assessments to monitor treatment effects and safety. These include evaluations of tumor response, organ function tests, cardiac ultrasound, and electrocardiograms. Researchers will measure outcomes such as pathological complete response and event-free survival over periods of 2 to 5 years. Participants will also be monitored for adverse events and followed up regularly for treatment adherence and health status throughout the study duration.

CONDITIONS

Brief Title

Neoadjuvant Chemotherapy in Combination With Toripalimab for HR+/HER2- Breast Cancer : a Randomized, Open-label, Parallel-controlled, Multi-center Phase III Study (NEOTORCH-BREAST04)

Research Team

Z

Zhijun Dai, Professor

Y

Youyi Chen

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here